

REMARKS

Applicant hereby elects, without traverse, prosecution of Group III, claims 15-18 and 24-29, which claims are directed to methods for treating hypergastrinemia with an immunogenic compound that reduces the hormone, gastrin. Applicants also elect from claim 17, the species of the G17 peptide SEQ ID NO: 1 as the species of the immunogenic compound referenced in generic claim 15.

Applicant acknowledges withdrawal of non-elected claims 7, 19-23 and 30-43.

The Commissioner is hereby authorized to charge any any fee due with this paper to our deposit account number 08-3040.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for Applicant

By Mary E. Bl
Mary E. Blak
Registration No. 31,215
Spring House Corporate Center
Box 457
Spring House, PA 19477
(215) 540-9200